It has been about a month since the last earnings report for Juno Therapeutics, Inc. . Shares have lost about 4.5% in the past month, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Juno Therapeutics Posts Wider-than-Expected First Quarter Loss
Juno Therapeutics reported first-quarter 2017 loss of $0.71 per share (including stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of $0.66. The quarterly loss, however, narrowed from the year-ago loss of $0.79 per share.
Total revenue stood at$19.3 million in the quarter compared with $9.8 million in the year-ago period. The top-line growth was mainly driven by revenues recognized under Juno’s collaboration agreement with Celgene and reimbursement of expenses related to research and development of CD19 candidates. Revenues also came in above the Zacks Consensus Estimate of $18 million.
The company’s adjusted research and development expenses in the reported quarter decreased 7.6% from the year-ago period to $75.1 million (including stock-based compensation expenses).
General and administrative expenses amounted to $20.7 million (including stock-based compensation expenses), up 29.4%. This was due to increased headcount to support the business, and consulting costs related to commercial readiness and personnel costs.
2017 Guidance
The company expects cash burn guidance outside the impact of any inflows or outflows from upfront payments related to business development in the range of $270–$300 million.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed an upward trend in fresh estimates. There has been one revision higher for the current quarter.
Juno Therapeutics, Inc. Price and Consensus
VGM Scores
At this time, Juno Therapeutics' stock has a poor Growth Score of 'F', however its Momentum is doing a lot better with an 'A'. The stock was allocated a grade of 'F' on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregte VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable solely for momentum investors based on our style scores.
Outlook
Estimates have been trending upward for the stock. The magnitude of these revisions also looks promising. However, the stock carries a Zacks Rank #5 (Strong Sell). We are expecting a below average return from the stock in the next few months.
Image: Bigstock
Juno Therapeutics (JUNO) Down 4.5% Since Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Juno Therapeutics, Inc. . Shares have lost about 4.5% in the past month, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Juno Therapeutics Posts Wider-than-Expected First Quarter Loss
Juno Therapeutics reported first-quarter 2017 loss of $0.71 per share (including stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of $0.66. The quarterly loss, however, narrowed from the year-ago loss of $0.79 per share.
Total revenue stood at$19.3 million in the quarter compared with $9.8 million in the year-ago period. The top-line growth was mainly driven by revenues recognized under Juno’s collaboration agreement with Celgene and reimbursement of expenses related to research and development of CD19 candidates. Revenues also came in above the Zacks Consensus Estimate of $18 million.
The company’s adjusted research and development expenses in the reported quarter decreased 7.6% from the year-ago period to $75.1 million (including stock-based compensation expenses).
General and administrative expenses amounted to $20.7 million (including stock-based compensation expenses), up 29.4%. This was due to increased headcount to support the business, and consulting costs related to commercial readiness and personnel costs.
2017 Guidance
The company expects cash burn guidance outside the impact of any inflows or outflows from upfront payments related to business development in the range of $270–$300 million.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed an upward trend in fresh estimates. There has been one revision higher for the current quarter.
Juno Therapeutics, Inc. Price and Consensus
Juno Therapeutics, Inc. Price and Consensus | Juno Therapeutics, Inc. Quote
VGM Scores
At this time, Juno Therapeutics' stock has a poor Growth Score of 'F', however its Momentum is doing a lot better with an 'A'. The stock was allocated a grade of 'F' on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregte VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable solely for momentum investors based on our style scores.
Outlook
Estimates have been trending upward for the stock. The magnitude of these revisions also looks promising. However, the stock carries a Zacks Rank #5 (Strong Sell). We are expecting a below average return from the stock in the next few months.